Viridian Therapeutics, Inc.\DE (VRDN) Non-Current Debt (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Non-Current Debt of $36.1 million for Q1 2026, up 74.48% year-over-year from $20.7 million in Q1 2025, and up 5.4% quarter-over-quarter from $34.2 million in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Non-Current Debt (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Non-Current Debt history runs 12 years deep, the most recent figure standing at $36.1 million for Q1 2026.
- In Q1 2026, Non-Current Debt rose 74.48% year-over-year to $36.1 million; the TTM figure through Mar 2026 stood at $36.1 million (up 74.48% YoY), while the FY2025 annual figure was $34.2 million, changed N/A from the prior year.
- Non-Current Debt for Q1 2026 stood at $36.1 million, up from $34.2 million in the prior quarter.
- The five-year high for Non-Current Debt was $36.1 million in Q1 2026, with the low at $4.6 million in Q2 2022.
- The 5-year median for Non-Current Debt is $20.0 million (2023), against an average of $16.4 million.
- The sharpest annual moves came in 2023 and 2025: Non-Current Debt soared 334.98% in 2023, then decreased 29.36% in 2025.
- Viridian Therapeutics, Inc.\DE's Non-Current Debt stood at $4.6 million in 2022, then jumped by 334.98% to $20.2 million in 2023, then advanced by 1.57% to $20.5 million in 2024, then surged by 66.86% to $34.2 million in 2025, then gained by 5.4% to $36.1 million in 2026.
- Business Quant data shows VRDN's Non-Current Debt at $36.1 million in Q1 2026, $34.2 million in Q4 2025, and $20.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | 113.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 113.64 Mn |
| Mar 31, 2026 | 36.09 Mn |
| Dec 31, 2025 | 34.24 Mn |
| Sep 30, 2025 | 20.89 Mn |
| Jun 30, 2025 | 12.35 Mn |
| Mar 31, 2025 | 20.69 Mn |
| Sep 30, 2024 | 20.52 Mn |
| Jun 30, 2024 | 17.49 Mn |
| Mar 31, 2024 | 20.33 Mn |
| Dec 31, 2023 | 20.21 Mn |
| Sep 30, 2023 | 20.00 Mn |
| Jun 30, 2023 | 4.71 Mn |
| Mar 31, 2023 | 4.68 Mn |
| Dec 31, 2022 | 4.65 Mn |
| Sep 30, 2022 | 4.61 Mn |
| Jun 30, 2022 | 4.59 Mn |
| Sep 30, 2020 | 4.13 Mn |
| Jun 30, 2020 | 5.38 Mn |
| Mar 31, 2020 | 3.39 Mn |
| Dec 31, 2019 | 4.33 Mn |